Legal & General Group Plc acquired a new position in shares of RadNet, Inc. (NASDAQ:RDNT – Free Report) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 158,695 shares of the medical research company’s stock, valued at approximately $9,787,000. Legal & General Group Plc owned about 0.20% of RadNet at the end of the most recent reporting period.
Several other institutional investors and hedge funds also recently made changes to their positions in the company. Crossmark Global Holdings Inc. lifted its position in shares of RadNet by 3.3% during the fourth quarter. Crossmark Global Holdings Inc. now owns 5,048 shares of the medical research company’s stock valued at $360,000 after purchasing an additional 163 shares in the last quarter. Summit Financial LLC grew its position in RadNet by 1.3% in the 4th quarter. Summit Financial LLC now owns 12,563 shares of the medical research company’s stock worth $896,000 after purchasing an additional 166 shares in the last quarter. Bank of Montreal Can increased its stake in RadNet by 3.3% in the 4th quarter. Bank of Montreal Can now owns 5,557 shares of the medical research company’s stock valued at $396,000 after buying an additional 180 shares during the last quarter. PNC Financial Services Group Inc. increased its stake in RadNet by 2.9% in the 1st quarter. PNC Financial Services Group Inc. now owns 7,392 shares of the medical research company’s stock valued at $413,000 after buying an additional 207 shares during the last quarter. Finally, Smartleaf Asset Management LLC lifted its position in shares of RadNet by 16.5% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,586 shares of the medical research company’s stock worth $113,000 after buying an additional 225 shares in the last quarter. Hedge funds and other institutional investors own 77.90% of the company’s stock.
Insider Buying and Selling at RadNet
In other RadNet news, CEO Cornelis Wesdorp sold 4,750 shares of the stock in a transaction on Tuesday, June 16th. The stock was sold at an average price of $58.11, for a total transaction of $276,022.50. Following the completion of the transaction, the chief executive officer directly owned 69,075 shares of the company’s stock, valued at approximately $4,013,948.25. This represents a 6.43% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director David L. Swartz sold 2,699 shares of the firm’s stock in a transaction on Thursday, June 18th. The stock was sold at an average price of $53.89, for a total value of $145,449.11. Following the completion of the sale, the director directly owned 177,013 shares of the company’s stock, valued at $9,539,230.57. This represents a 1.50% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 5.14% of the stock is currently owned by corporate insiders.
Wall Street Analyst Weigh In
Get Our Latest Research Report on RadNet
RadNet Stock Up 1.6%
RDNT opened at $75.82 on Tuesday. The company has a quick ratio of 1.48, a current ratio of 1.48 and a debt-to-equity ratio of 0.94. The stock has a market cap of $5.97 billion, a price-to-earnings ratio of -280.80 and a beta of 1.36. RadNet, Inc. has a twelve month low of $50.82 and a twelve month high of $85.84. The company’s 50-day moving average price is $67.71 and its two-hundred day moving average price is $62.28.
RadNet (NASDAQ:RDNT – Get Free Report) last issued its quarterly earnings results on Monday, August 10th. The medical research company reported $0.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.20 by $0.09. The company had revenue of $622.72 million during the quarter, compared to analyst estimates of $610.87 million. RadNet had a negative net margin of 0.93% and a positive return on equity of 2.61%. RadNet’s quarterly revenue was up 25.0% compared to the same quarter last year. During the same quarter last year, the business posted $0.31 EPS. As a group, equities analysts expect that RadNet, Inc. will post 0.49 earnings per share for the current year.
About RadNet
RadNet, Inc is a leading independent provider of outpatient diagnostic imaging services in the United States. Through a nationwide network of fixed-site imaging centers and affiliated joint-venture locations, the company delivers a comprehensive suite of radiology services including MRI, CT, PET/CT, ultrasound, X-ray, mammography, bone densitometry, nuclear medicine and interventional radiology procedures. RadNet also offers teleradiology and imaging management solutions to physician practices, hospitals and healthcare systems.
Founded in 1981 and headquartered in Los Angeles, RadNet has expanded its footprint organically and through strategic acquisitions.
Featured Stories
- Five stocks we like better than RadNet
- Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season
- Insiders Are Betting Big on These 3 Healthcare Stocks
- 3 Stocks for Investors Who Still Believe Cash Is King
- Dollar General and Dollar Tree Are Recovering, But Not for the Same Reason
Receive News & Ratings for RadNet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RadNet and related companies with MarketBeat.com's FREE daily email newsletter.
